<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05457868</url>
  </required_header>
  <id_info>
    <org_study_id>2019A010961-9</org_study_id>
    <nct_id>NCT05457868</nct_id>
  </id_info>
  <brief_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists</brief_title>
  <official_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset&#xD;
      between patients treated with medications that target specific metabolic pathways and&#xD;
      patients treated with alternative medications for the same indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham&#xD;
      and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical&#xD;
      and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National&#xD;
      Institute on Aging (NIA) intramural research program. This study aims to evaluate the&#xD;
      comparative risk of dementia/Alzheimer's disease onset between patients treated with&#xD;
      medications that target specific metabolic pathways and patients treated with alternative&#xD;
      medications for the same indication using healthcare claims data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Actual">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to dementia onset</measure>
    <time_frame>Through study completion (a median of 120 days)</time_frame>
    <description>Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Alzheimer's disease onset</measure>
    <time_frame>Through study completion (a median of 120 days)</time_frame>
    <description>Time to Alzheimer's disease onset. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">124117</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Salbutamol</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-acting muscarinic antagonists (LAMA)</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Salbutamol claim is used as the exposure group.</description>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAMA</intervention_name>
    <description>Long-acting muscarinic antagonists (LAMA) - umeclidinium, aclidinium, tiotropium, glycopyrolate, glycopyrronium - claim is used as the reference group.</description>
    <arm_group_label>Long-acting muscarinic antagonists (LAMA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will employ a new user, active comparator, observational cohort study design&#xD;
        comparing Salbutamol versus Long-acting muscarinic antagonists (LAMAs). The patients will&#xD;
        be required to have continuous enrollment during the baseline period of 365 days before&#xD;
        initiation of study drugs (cohort entry/index date). Follow-up for the outcome (dementia)&#xD;
        differs between analyses. Follow-up begins the day after drug initiation (analysis 1, 3,&#xD;
        4); 180 days after drug initiation (analysis 2).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Please see&#xD;
        https://docs.google.com/spreadsheets/d/1j53_NBnEVQik4Ps5a9pZOvuHm1mWHCRZ3DAvI0y8NO8/edit?us&#xD;
        p=sharing or Appendix A&#xD;
        (https://drive.google.com/file/d/1uC_G8TJ1ujoJbas1p1gFaYFzY7Hw7xMq/view?usp=sharing) for&#xD;
        full code and algorithm definitions.&#xD;
&#xD;
        Medicare timeframe: 2008 to 2018 (end of data availability).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged &gt;/= 65 years on the index date&#xD;
&#xD;
          -  2. No prior use of Salbutamol and Long-acting Muscarinic Antagonists (LAMA) anytime&#xD;
             prior to cohort entry date&#xD;
&#xD;
          -  3. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to&#xD;
             and including cohort entry date&#xD;
&#xD;
          -  4. At least two claims with COPD diagnosis measured 365 days prior to drug initiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Prior history of dementia measured anytime prior to cohort entry date&#xD;
&#xD;
          -  2. Prior history of nursing home admission in the 365 days prior to the cohort entry&#xD;
             date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhav Thambisetty, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>July 11, 2022</study_first_submitted>
  <study_first_submitted_qc>July 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2022</study_first_posted>
  <last_update_submitted>August 30, 2022</last_update_submitted>
  <last_update_submitted_qc>August 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Rishi J. Desai</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT05457868/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

